{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:50:19Z","timestamp":1792363819055,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-022743"],"award-info":[{"award-number":["MJFF-022743"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-024503"],"award-info":[{"award-number":["MJFF-024503"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding how meaningful symptoms and impacts of Parkinson\u2019s change with time is necessary to select endpoints for clinical trials and to support clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to longitudinally evaluate the prevalence, bothersomeness, and functional impacts of early Parkinson\u2019s symptoms on daily life over a three-year study duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>32 participants with early Parkinson\u2019s completed qualitative interviews to map symptoms and impacts of disease annually for three years. Symptom maps were content coded for frequency and bothersomeness of symptoms and presence of related impacts. Non-parametric generalized linear mixed models (GLMM) were used to evaluate change over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most bothersome motor symptoms were tremor, gait difficulties, balance, fine motor, slow movements, and stiffness at all years. Top non-motor symptoms were fatigue, sleep, mood changes, difficulty thinking, and quiet voice. Of these, only gait and balance changed significantly over the study duration. By contrast, many functional impacts changed significantly, with all reporting increased work of living and greater effort to do usual activities by year 3. At the same time, participants reported increased ability to cope and compensate by making positive life changes which mitigated the bothersomeness of symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Other than gait and balance, few Parkinson\u2019s symptoms increased significantly in bothersomeness over three years. However, functional and psychosocial impacts of symptoms, often attributed to more than one cause, were more sensitive to change over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13615-5","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:54:08Z","timestamp":1769010848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Three years later: tracking bothersome symptoms and impacts for people with early Parkinson\u2019s disease"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-9183","authenticated-orcid":false,"given":"Jennifer R.","family":"Mammen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirinda","family":"Tyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Magan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Thimaikhue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Thao-Uyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Solodova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Auinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kostrzebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuge","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"13615_CR1","unstructured":"USDHHS. Patient-focused drug development (PFDD1): Collecting comprehensive and representative input. 2018 2022; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input."},{"key":"13615_CR2","unstructured":"USDHHS. Patient-focused drug development (PFDD2): Methods to identify what is important to patients (Guidance for industry, food and drug administration staff, and other stakeholders). 2022 2022; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients."},{"key":"13615_CR3","doi-asserted-by":"crossref","unstructured":"USDHHS. Patient-focused drug development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments (Guidance 3). 2022 June 2022; Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome.","DOI":"10.1007\/s40271-022-00607-6"},{"issue":"1","key":"13615_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-025-00907-2","volume":"11","author":"JR Mammen","year":"2025","unstructured":"Mammen JR, Adams JL et al (2025) Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson\u2019s disease. npj Parkinsons Dis. 11(1):65","journal-title":"npj Parkinsons Dis."},{"key":"13615_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00375-3","author":"T Morel","year":"2022","unstructured":"Morel T et al (2022) Patient experience in early-stage Parkinson\u2019s disease: using a mixed methods analysis to identify which concepts are cardinal for clinical trial outcome assessment. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-022-00375-3","journal-title":"Neurol Ther"},{"issue":"2","key":"13615_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JPD-202346","volume":"11","author":"RJ Port","year":"2021","unstructured":"Port RJ et al (2021) People with Parkinson\u2019s disease: what symptoms do they most want to improve and how does this change with disease duration? J Parkinsons Dis 11(2):715\u2013724","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"13615_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mdc3.14321","volume":"12","author":"A Lerner","year":"2025","unstructured":"Lerner A et al (2025) Fox insight: most bothersome symptoms in early-stage Parkinson\u2019s disease. Mov Disord Clin Pract 12(4):510\u2013515","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"13615_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JPD-202457","volume":"12","author":"H Staunton","year":"2022","unstructured":"Staunton H et al (2022) A patient-centered conceptual model of symptoms and their impact in early Parkinson\u2019s disease: a qualitative study. J Parkinsons Dis 12(1):137\u2013151","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"13615_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00415-024-12789-0","volume":"272","author":"JR Mammen","year":"2025","unstructured":"Mammen JR et al (2025) Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson\u2019s. J Neurol 272(2):114","journal-title":"J Neurol"},{"issue":"1","key":"13615_CR10","doi-asserted-by":"publisher","first-page":"21171","DOI":"10.1038\/s41598-024-71555-4","volume":"14","author":"JR Mammen","year":"2024","unstructured":"Mammen JR et al (2024) Understanding what aspects of Parkinson\u2019s disease matter most to patients and families. Sci Rep 14(1):21171","journal-title":"Sci Rep"},{"issue":"1","key":"13615_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41531-024-00721-2","volume":"10","author":"JL Adams","year":"2024","unstructured":"Adams JL et al (2024) Using a smartwatch and smartphone to assess early Parkinson\u2019s disease in the WATCH-PD study over 12 months. NPJ Parkinsons Dis 10(1):112","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"13615_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-225122","volume":"13","author":"J Mammen","year":"2023","unstructured":"Mammen J et al (2023) Mapping meaningful symptoms and impacts of disease to digital outcome measures. J Parkinson\u2019s Disease 13(4):589\u2013607","journal-title":"J Parkinson\u2019s Disease"},{"issue":"2","key":"13615_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA et al (2009) Research electronic data capture (REDCap)\u2014a metadata\u2011driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"issue":"1","key":"13615_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-025-00907-2","volume":"11","author":"JR Mammen","year":"2025","unstructured":"Mammen JR et al (2025) Systematic review and consensus conceptual model of meaningful symptoms and functional impacts in early Parkinson\u2019s disease. NPJ Parkinsons Dis 11(1):65","journal-title":"NPJ Parkinsons Dis"},{"key":"13615_CR15","unstructured":"XMind. Version 3.4.1 n.d. February 7, 2016]; Available from: http:\/\/www.xmind.net."},{"issue":"12","key":"13615_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"P de la Riva","year":"2014","unstructured":"de la Riva P et al (2014) Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 83(12):1096\u20131103","journal-title":"Neurology"},{"issue":"2","key":"13615_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.26077","volume":"30","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer C et al (2015) The onset of nonmotor symptoms in Parkinson\u2019s disease (the ONSET PD study). Mov Disord 30(2):229\u2013237","journal-title":"Mov Disord"},{"issue":"8","key":"13615_CR18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","volume":"266","author":"A Regnault","year":"2019","unstructured":"Regnault A et al (2019) Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s progression marker initiative cohort. J Neurol 266(8):1927\u20131936","journal-title":"J Neurol"},{"key":"13615_CR19","doi-asserted-by":"publisher","DOI":"10.2196\/44206","volume":"25","author":"A Keogh","year":"2023","unstructured":"Keogh A et al (2023) Mobilizing patient and public involvement in the development of real-world digital technology solutions: tutorial. J Med Internet Res 25:e44206","journal-title":"J Med Internet Res"},{"issue":"7","key":"13615_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038704","volume":"10","author":"AM Polhemus","year":"2020","unstructured":"Polhemus AM et al (2020) Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review. BMJ Open 10(7):e038704","journal-title":"BMJ Open"},{"issue":"4","key":"13615_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-225122","volume":"13","author":"JR Mammen","year":"2023","unstructured":"Mammen JR, Speck RM, Stebbins GM, M\u00fcller MLTM, Yang PT, Campbell M, Cosman J, Crawford JE, Dam T, Hellsten J, Jensen-Roberts S, Kostrzebski M, Simuni T, Barowicz KW, Cedarbaum JM, Dorsey ER, Stephenson D, Adams JL (2023) Mapping relevance of digital measures to meaningful symptoms and impacts in early Parkinson\u2019s disease. J Parkinsons Dis 13(4):589\u2013607. https:\/\/doi.org\/10.3233\/JPD-225122","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"13615_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/NRE-130828","volume":"32","author":"SA Combs","year":"2013","unstructured":"Combs SA et al (2013) Community-based group exercise for persons with Parkinson disease: a randomized controlled trial. NeuroRehabilitation 32(1):117\u2013124","journal-title":"NeuroRehabilitation"},{"issue":"3","key":"13615_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/35425","volume":"5","author":"EV Gerritzen","year":"2022","unstructured":"Gerritzen EV et al (2022) Online peer support for people with Parkinson disease: narrative synthesis systematic review. JMIR Aging 5(3):e35425","journal-title":"JMIR Aging"},{"issue":"1","key":"13615_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00452-w","volume":"9","author":"JYY Kwok","year":"2023","unstructured":"Kwok JYY et al (2023) A randomized clinical trial of mindfulness meditation versus exercise in Parkinson\u2019s disease during social unrest. NPJ Parkinsons Dis 9(1):7","journal-title":"NPJ Parkinsons Dis"},{"key":"13615_CR25","volume":"2015","author":"B Pickut","year":"2015","unstructured":"Pickut B et al (2015) Mindfulness training among individuals with Parkinson\u2019s disease: neurobehavioral effects. Parkinsons Dis 2015:816404","journal-title":"Parkinsons Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13615-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:05:01Z","timestamp":1773785101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13615-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13615"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13615-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest relevant to this work. Jennifer Mammen has received grants and research support from NIH\/NINR, FDA\/CDER, Michael J. Fox Foundation for Parkinson\u2019s Research, Critical Path for Parkinson\u2019s, and and\/or consulting fees or honoraria from Michael J. Fox Foundation for Parkinson\u2019s Research and Lundbeck. Mirinda Tyo has received grants and research support from Michael J. Fox Foundation for Parkinson\u2019s Research and FDA\/CDER and consulting fees or honoraria from Michael J. Fox Foundation for Parkinson\u2019s Research. Yuge Xiao is an employee at Michael J. Fox Foundation for Parkinson\u2019s Research. Jamie Adams received research support from the Michael J. Fox Foundation for Parkinson\u2019s Research, Critical Path for Parkinson\u2019s, NIH\/NINDS, U.S. Food and Drug Administration, Biogen, the Huntington Study Group, and PhotoPharmics; and compensation or honoraria from the Huntington Study Group, the Parkinson Study Group, AbbVie, VisualDx, BioSensics, Sana Biotechnology, Neuron23, Lundbeck, Biohaven, the Parkinson Study Group, and American Neurological Association. The remaining co-authors have no additional financial disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed electronic consent was obtained via Redcap.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was approved by University of Rochester IRB#00006429 and University of Massachusetts, Dartmouth IRB#23.044.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"This study used COREQ criteria to guide reporting of qualitative findings.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Quality in qualitative research statement"}}],"article-number":"93"}}